KDC-MN-1354 – Kodiac biolabs

Our opinion on this compoundNovel, promising

59/100

The only Type I PAM for alpha-7 nAChR in clinical development, mechanistically sound rationale undermined by thin evidence and stalled pipeline

Look, the alpha-7 nicotinic space has been a graveyard for drug development. Encenicline, the partial agonist Envivo advanced to Phase 3, hit an FDA clinical hold in September 2015 and was terminated in March 2016 after severe gastrointestinal adverse events. GTS-21, bradanicline, others have all stalled or returned disappointing effect sizes. What makes AVL-3288 genuinely interesting is that it approaches the target from a completely different angle, and the argument for that angle is mechanistically sound rather than just repositioning rhetoric.

AVL-3288 is a Type I positive allosteric modulator. It doesn’t bind the orthosteric acetylcholine site and doesn’t directly activate the receptor in the absence of endogenous agonist. Instead it enhances the potency and efficacy of acetylcholine when it arrives naturally at the synapse. Crucially, it preserves rapid desensitization kinetics, meaning the alpha-7 channel still closes on its normal timescale after activation. Direct agonists prolong receptor activation, which is probably why encenicline-class compounds produced the GI toxicity they did; those receptors are expressed throughout the gut. The Type I PAM approach lets physiology govern the signaling envelope, and thats a real mechanistic distinction, not marketing copy.

The clinical record is real but modest. Phase 1a (Gee et al. 2017, N=21 healthy non-smokers) established oral bioavailability, dose-proportional pharmacokinetics, and exploratory cognitive signals at 10 and 30 milligrams. Phase 1b (Freedman et al. 2020, N=24, randomized double-blind placebo-controlled triple-crossover in medicated schizophrenia outpatients) showed P50 auditory evoked potential gating effects at 30 milligrams. P50 gating is a well-validated biomarker of alpha-7 target engagement in the schizophrenia field, so that signal carries real weight. But N=24 in a crossover is a thin foundation, and Phase 2 hasn’t happened. Development currently depends on commercial funding that hasn’t materialized.

We think AVL-3288 is a genuinely useful research tool for anyone doing serious alpha-7 work. Thats the core bench-value argument: if you want to ask what endogenous cholinergic modulation does versus direct receptor activation, this compound lets you answer that question in a way that partial agonists cant. Compared to tropisetron, which brings 5-HT3 antagonism along as a confound, AVL-3288 is a cleaner alpha-7-specific probe. Preclinical work in TBI and Alzheimer models adds credible signal. What we dont like is that sourcing is genuinely difficult, the isoxazole-acrylamide scaffold has specific geometric constraints that complicate vendor verification, and the full translational arrow has only been drawn once in small academic-linked trial sets.

For investigators working alpha-7 biology, cholinergic cognitive neuroscience, or neuroinflammation via the JAK2/STAT3 anti-inflammatory angle, AVL-3288 fills a niche nothing else in the class currently occupies. The honest read: mechanistically compelling, small-but-real human signal, sitting in development limbo. The score reflects a strong mechanistic and differentiation case held back by genuinely thin evidence and a pipeline that hasn’t moved in years.

Novelty: 60
Mechanism promise: 75
In-category differentiation: 72
Evidence quality: 33
Translational signal: 43
Research bench value: 62

Rationale Scores high on mechanism and differentiation because the Type I PAM approach is genuinely distinct from the failed agonist class and preserves physiological signaling specificity in a way that carries real scientific logic. Evidence quality and translational signal are limited by small Phase 1 Ns (21 and 24 subjects) and the absence of Phase 2 data, which keeps overall below the 65+ range despite the mechanistic case.

Type I positive allosteric modulator of the alpha-7 nicotinic acetylcholine receptor

An isoxazole-acrylamide chemical entity originally developed at the University of California Irvine as compound CCMI and licensed through multiple owners to Anvylic Therapeutics, representing the most mechanistically distinct alpha-7 nicotinic candidate in clinical development through its Type I positive allosteric modulator mechanism that preserves the spatiotemporal specificity of endogenous cholinergic neurotransmission.

Abstract

AVL-3288 (also known as UCI-4083, CCMI, Anvylic-3288, and XY-4083) is a small-molecule, orally bioavailable Type I positive allosteric modulator (PAM) of the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor (alpha-7 nAChR). The compound is mechanistically distinct from the partial-agonist (tropisetron, encenicline, GTS-21) and full-agonist (bradanicline, PHA-543613) classes that have dominated alpha-7 nicotinic receptor drug development. Type I PAMs bind the alpha-7 receptor at an allosteric site distinct from the orthosteric (acetylcholine) binding site, do not directly activate the receptor in the absence of agonist, and enhance the potency and efficacy of endogenous acetylcholine signaling at the receptor. Critically, Type I PAMs preserve the rapid desensitization kinetics of the alpha-7 channel and therefore preserve the spatiotemporal specificity of cholinergic neurotransmission, in contrast to direct agonists which prolong receptor activation and may produce non-physiological signaling. This mechanistic profile is the principal scientific argument for the AVL-3288 approach as an alternative to direct agonist development in cognitive applications, particularly in light of the September 2015 FDA clinical hold and March 2016 Phase 3 termination of encenicline (a partial agonist) for severe gastrointestinal toxicity. The compound was originated at the University of California Irvine in the laboratory of Kelvin Gee in the early 2000s as part of an academic medicinal-chemistry program for novel alpha-7 nicotinic receptor modulators, was licensed through several commercial owners (Bionomics, Anvylic Therapeutics), and was advanced through a first-in-human Phase 1a single-ascending-dose study in 21 healthy non-smokers (Gee et al. 2017) and a Phase 1b randomized double-blind placebo-controlled triple-cross-over study in 24 non-smoking medicated outpatients with schizophrenia or schizoaffective disorder (Freedman et al. 2020) at 10 milligrams and 30 milligrams oral doses. The Phase 1a study reported safety, dose-proportional pharmacokinetics, and exploratory cognitive signals at 10 and 30 milligrams. The Phase 1b study in schizophrenia patients reported P50 auditory evoked potential gating biomarker effects at 30 milligrams (consistent with alpha-7 receptor target engagement), exploratory cognitive performance signals, and acceptable tolerability across the studied doses. The compound has not advanced to Phase 2 as of the most recent monograph revision; future development depends on commercial-funding decisions. AVL-3288 represents the most mechanistically novel of the alpha-7 nicotinic receptor candidates and is the principal contemporary alternative therapeutic concept for the alpha-7 nicotinic target. This monograph reviews the chemistry, synthesis, and structural class of AVL-3288; the receptor pharmacology of Type I PAM mechanism in molecular and electrophysiological detail; the limited human pharmacokinetic record from Phase 1a and Phase 1b; the clinical evidence base in healthy volunteers and schizophrenia outpatients; sourcing, reconstitution, and stack-interaction considerations; the safety record; and a structured comparative assessment of five alpha-7 nicotinic acetylcholine receptor candidates against AVL-3288 on the five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1354Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1354

AVL-3288

Abstract

Read the full monograph